About EYLEA and Macular Edema following Retinal Vein Occlusion About EYLEA and Macular Edema following Retinal Vein Occlusion

EYLEA & MEfRVO

Learn more about the #1 prescribed FDA-approved anti-vascular endothelial growth factor treatment for patients with Macular Edema following Retinal Vein Occlusion (MEfRVO).

ABOUT EYLEA

EYLEA has been studied in more than 3,000 people with certain diseases of the retina.

EYLEA is a prescription medicine given by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

HOW EYLEA WORKS

EYLEA is an anti–vascular
endothelial growth factor
(anti-VEGF) treatment that is given by injection into the eye and works by blocking VEGF. EYLEA blocks VEGF by trapping it between its molecular arms.

Anti-vascular endothelial growth factor (anti-VEGF) treatment

WHAT IS VEGF

VEGF is a protein that, at high levels, can cause blood vessels to leak fluid and also result in the growth of abnormal blood vessels. Symptoms of MEfRVO happen as the macula swells with fluid. Blocking VEGF helps reduce the fluid leaking into the macula.

Vision improvements seen with EYLEA

  • MEfCRVO
  • MEfBRVO

Macular Edema following Central Retinal Vein Occlusion (MEfCRVO)

In two clinical studies, 358 people with MEfCRVO received injections of EYLEA (2 mg) either once every 4 weeks or control

Both studies measured the percentage of people gaining at least 15 letters (3 lines) on the eye chart at 6 months compared to the number of letters they saw when each study started.

56% to 60% of patients with Macular Edema following Central Retinal Vein Occlusion that were treated with EYLEA gained at least 15 letters on the eye chart.

At 6 months, 56% to 60% of people treated with EYLEA gained at least 15 letters (3 lines) on the eye chart. 89% to 94% of people treated with EYLEA were able to see the same number of letters or more letters on the eye chart.

Eye chart before EYLEA anti-VEGF.
Letters gained on eye chart after EYLEA anti-VEGF measured at 6 months.

At 6 months, people treated with EYLEA saw, on average, at least 17 more letters than when each study started.

The number of letters gained by people treated with EYLEA was much greater than control.

These results are from 2 clinical studies; your individual results may vary. Discuss with your eye care team if EYLEA is right for you.

Macular Edema following Branch Retinal Vein Occlusion (MEfBRVO)

In a clinical study, 181 people with MEfBRVO received injections of EYLEA (2 mg) either once every 4 weeks or control.

The study measured the percentage of people gaining at least 15 letters (3 lines) on the eye chart at 6 months compared to the number of letters they saw when the study started.

53% of patients with Macular Edema following Branch Retinal Vein Occlusion that were treated with EYLEA gained at least 15 letters on the eye chart.

At 6 months, 53% of people treated with EYLEA gained at least 15 letters (3 lines) on the eye chart. 98% of people treated with EYLEA were able to see the same number of letters or more letters on the eye chart.

Eye chart before EYLEA anti-VEGF.
Letters gained on eye chart after EYLEA anti-VEGF measured at 1 and 2 years.

At 6 months, people treated with EYLEA saw, on average, at least 17 more letters than when each study started.

The number of letters gained by people treated with EYLEA was much greater than control.

These results are from a clinical study; your individual results may vary. Discuss with your eye care team if EYLEA is right for you.

Recommended dosing

IT'S IMPORTANT TO KEEP UP WITH YOUR TREATMENT SCHEDULE

The recommended dose of EYLEA for RVO is 2 mg administered by injection in the eye once every 4 weeks (approximately every 25 days, monthly).

Your eye care team will want to see you regularly to check your vision and also check your treatment progress with EYLEA. Work with your eye care team to make sure you can keep your appointments and stay on your recommended treatment schedule.

Safety information for EYLEA

EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.

In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.

There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.

Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.

The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, moving spots in the field of vision, and increased pressure in the eye.

As with all therapeutic proteins, there is a potential for an immune response in patients treated with EYLEA.

It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.

FINANCIAL SUPPORT FROM EYLEA4U®

MONITORING YOUR VISION IS IMPORTANT

EYLEA4U® logo

EYLEA4U is a comprehensive support program with several resources available to help eligible patients with the cost of EYLEA.

Learn about vision tests.

Learn about some of the tests your doctor may use to diagnose and monitor your condition, and what you can do at home.

IMPORTANT SAFETY INFORMATION
  • EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, moving spots in the field of vision, and increased pressure in the eye.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients with DME.

Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.

For U.S. Residents Only

EYLEA AND EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

© 2019, Regeneron Pharmaceuticals, Inc. All rights reserved.
777 Old Saw Mill River Road,
Tarrytown, NY 10591

03/2019
US-LEA-14281d(1) US-LEA-14281d(1)

 

Searching with Lea

Close
MENU